Edwards Lifesciences Corporation (NYSE:EW) Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 47.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,101 shares of the medical research company's stock after selling 15,654 shares during the quarter. Bessemer Group Inc.'s holdings in Edwards Lifesciences were worth $1,240,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Lecap Asset Management Ltd. purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth $2,909,000. Asset Management One Co. Ltd. boosted its position in shares of Edwards Lifesciences by 3.4% during the 1st quarter. Asset Management One Co. Ltd. now owns 250,089 shares of the medical research company's stock worth $18,126,000 after acquiring an additional 8,271 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in shares of Edwards Lifesciences by 9.7% during the 1st quarter. Oppenheimer & Co. Inc. now owns 65,894 shares of the medical research company's stock worth $4,776,000 after acquiring an additional 5,853 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Edwards Lifesciences by 23.5% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 21,699 shares of the medical research company's stock worth $1,573,000 after acquiring an additional 4,125 shares in the last quarter. Finally, Kentucky Retirement Systems Insurance Trust Fund raised its position in shares of Edwards Lifesciences by 339.2% during the 1st quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 17,016 shares of the medical research company's stock worth $1,233,000 after acquiring an additional 13,142 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

NYSE:EW traded down $0.25 during trading hours on Thursday, hitting $76.77. The company's stock had a trading volume of 1,679,364 shares, compared to its average volume of 5,224,048. Edwards Lifesciences Corporation has a 52-week low of $58.93 and a 52-week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. The business's 50-day moving average is $76.07 and its two-hundred day moving average is $73.24. The company has a market capitalization of $45.03 billion, a PE ratio of 10.97, a PEG ratio of 3.89 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The business had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. During the same period in the prior year, the company posted $0.66 EPS. The business's revenue for the quarter was up 6.2% on a year-over-year basis. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research analyst reports. Robert W. Baird upped their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a report on Thursday, April 24th. Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a report on Friday, April 25th. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Finally, Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of "Hold" and a consensus target price of $80.20.

Insider Activity at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian sold 5,980 shares of the company's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $74.91, for a total value of $447,961.80. Following the sale, the chief executive officer owned 58,284 shares in the company, valued at $4,366,054.44. This represents a 9.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction on Friday, May 9th. The stock was sold at an average price of $74.40, for a total value of $837,000.00. Following the sale, the chief financial officer owned 41,098 shares in the company, valued at approximately $3,057,691.20. The trade was a 21.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,648 shares of company stock worth $2,998,866. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.